• First commercial sales of Remplir in Hong Kong, a key milestone
• Remplir now selling in Australia, New Zealand, Singapore, US, and Hong Kong
• Hong Kong represents significant growth opportunity in Greater Bay Area

Orthocell is pleased to announce the first commercial sales of Remplir in Hong Kong, representing a key milestone in the company's Asian growth strategy. These initial sales follow the successful introduction of Remplir in Hong Kong, including its first surgical use and strong reception at the Hong Kong Orthopaedic Association (HKOA) 45th Annual Congress. The first sales to MontsMed provide immediate in-market availability and are expected to support multiple downstream sales as surgeons adopt the technology. Orthocell continues to execute its global commercialisation strategy, with Remplir now selling in Australia, New Zealand, Singapore, the US, and Hong Kong, with first sales expected in Canada and Thailand in the near term. Hong Kong represents a significant growth opportunity, serving as a strategic entry point into the Guangdong-Hong Kong-Macao Greater Bay Area (GBA), a rapidly developing healthcare market of approximately 100 million people. Together with MontsMed, Orthocell is strongly positioned to drive market penetration through leading hospitals and specialist surgeons across the region. Orthocell remains well funded with ~A$50 million in cash and no debt, enabling the company to continue expanding its global footprint and delivering on its commercialisation objectives.

Orthocell expects to deliver a step change in revenue in FY26 as it continues to drive rapid product adoption globally.

Orthocell is well-positioned to support its distributor MontsMed in driving Remplir adoption across leading hospitals in Hong Kong and the Greater Bay Area. The company's recently appointed Asia Pacific Commercial Director will further accelerate commercial traction in the region from Q1 CY26.